Welcome to our dedicated page for Simulations Plus SEC filings (Ticker: SLP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Simulations Plus, Inc. (Nasdaq: SLP) SEC filings page on Stock Titan provides access to the company’s official regulatory disclosures, including annual and quarterly reports, proxy statements, and current reports on Form 8‑K. As a California corporation in the professional, scientific, and technical services sector, Simulations Plus files with the U.S. Securities and Exchange Commission under file number 001‑32046.
Annual reports on Form 10‑K and quarterly reports on Form 10‑Q give detailed information on the company’s software and services segments, revenue mix, cost structure, research and development spending, and risk factors related to its biosimulation, cheminformatics, and consulting activities. These filings also describe the integration of AI/ML, PBPK, QSP/QST, and related modeling approaches that underpin its model‑informed and AI‑accelerated drug development offerings.
Proxy statements (DEF 14A) include information on board elections, auditor ratification, and equity incentive plans. For example, the company’s definitive proxy statement details proposals such as increasing shares authorized under the 2021 Equity Incentive Plan, board and committee structures, corporate governance practices, and executive compensation frameworks.
Current reports on Form 8‑K disclose material events such as changes in the independent registered public accounting firm, preliminary financial results and guidance, executive employment agreements, and scheduling of earnings releases and conference calls. These documents help investors understand governance decisions, auditor transitions, and key operational updates.
On Stock Titan, these filings are paired with AI‑powered summaries that highlight important points from lengthy documents, helping readers quickly identify items such as segment performance discussions, non‑GAAP reconciliations, equity plan amendments, and auditor changes. Users can also review filings related to compensation and equity awards, as well as other disclosures that shape the regulatory and governance profile of Simulations Plus.
Simulations Plus (SLP), a provider of cheminformatics and biosimulation solutions for the biopharma industry, announced a rescheduling of its Q3 FY2025 financial results release and conference call. The company has delayed these events from the original date of July 2, 2025, to the following schedule:
- Conference call: July 14, 2025, at 5:00 p.m. Eastern Time
- Financial results release: July 15, 2025, before market open
The delay utilizes the maximum time allowed under regulations following the company's status change from a large accelerated filer to a non-accelerated filer. This material event was reported via Form 8-K and includes a press release (Exhibit 99.1) containing the rescheduling details. The filing indicates a notable change in the company's filing status and timing of financial disclosures, which could be significant for investors tracking reporting obligations and corporate governance.